Literature DB >> 2647490

Mutant proteins of human interleukin 2. Renaturation yield, proliferative activity and receptor binding.

U Weigel1, M Meyer, W Sebald.   

Abstract

Muteins, i.e. proteins altered by mutation of their genes, of interleukin 2 (Il2) were generated by oligonucleotide-directed mutagenesis in vitro. All acidic and basic residues conserved between man and mouse were exchanged as well as four lipophilic residues contained within four hydrophobic segments of the protein. The muteins were produced in Escherichia coli and submitted to a renaturation and purification protocol, before bioactivity and receptor binding of each of them was determined. All muteins besides two (K44/T125 and Q110/T125) could be renatured and purified. One mutein (K94/T125) exhibited a more than tenfold-improved renaturation yield. One amino exchange (Asp-20 to Asn) resulted in an about 20-fold reduction in proliferative activity and high-affinity receptor binding. The binding to the low-affinity Il2-binding protein (Tac antigen) was unimpaired. A second exchange (Arg-38 to Gln) had no effect on proliferative activity. The binding to both the high- and the low-affinity receptor, however, was reduced about 20-fold. Preliminary trials on the stability of these muteins by guanidinium hydrochloride denaturation studies detected no differences between wild-type interleukin 2 and muteins. It is suggested that Asp-20 forms part of the binding site for the large receptor subunit whereas Arg-38 is involved in the contact site to the small subunit.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647490     DOI: 10.1111/j.1432-1033.1989.tb14647.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  12 in total

1.  Binding of small molecules to an adaptive protein-protein interface.

Authors:  Michelle R Arkin; Mike Randal; Warren L DeLano; Jennifer Hyde; Tinh N Luong; Johan D Oslob; Darren R Raphael; Lisa Taylor; Jun Wang; Robert S McDowell; James A Wells; Andrew C Braisted
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-11       Impact factor: 11.205

2.  Successful spinal fusion by E. coli-derived BMP-2-adsorbed porous beta-TCP granules: a pilot study.

Authors:  Sho Dohzono; Yuuki Imai; Hiroaki Nakamura; Shigeyuki Wakitani; Kunio Takaoka
Journal:  Clin Orthop Relat Res       Date:  2009-07-07       Impact factor: 4.176

3.  Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor.

Authors:  K Sauvé; M Nachman; C Spence; P Bailon; E Campbell; W H Tsien; J A Kondas; J Hakimi; G Ju
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

4.  Efficacy of interspinous process lumbar fusion with recombinant human bone morphogenetic protein-2 delivered with a synthetic polymer and β-tricalcium phosphate in a rabbit model.

Authors:  Tomiya Matsumoto; Hiromitsu Toyoda; Sho Dohzono; Hiroyuki Yasuda; Shigeyuki Wakitani; Hiroaki Nakamura; Kunio Takaoka
Journal:  Eur Spine J       Date:  2011-12-28       Impact factor: 3.134

5.  The interleukin 2 receptor (IL-2R): the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit.

Authors:  A J Grant; E Roessler; G Ju; M Tsudo; K Sugamura; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

6.  Osteoinductive capacity and heat stability of recombinant human bone morphogenetic protein-2 produced by Escherichia coli and dimerized by biochemical processing.

Authors:  Koichi Yano; Masatoshi Hoshino; Yoichi Ohta; Tomoya Manaka; Yoshifumi Naka; Yuuki Imai; Walter Sebald; Kunio Takaoka
Journal:  J Bone Miner Metab       Date:  2009-02-21       Impact factor: 2.626

7.  Receptor binding properties of four-helix-bundle growth factors deduced from electrostatic analysis.

Authors:  E Demchuk; T Mueller; H Oschkinat; W Sebald; R C Wade
Journal:  Protein Sci       Date:  1994-06       Impact factor: 6.725

8.  Partial agonist/antagonist mouse interleukin-2 proteins indicate that a third component of the receptor complex functions in signal transduction.

Authors:  S M Zurawski; J L Imler; G Zurawski
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

9.  Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement.

Authors:  N Kruse; H P Tony; W Sebald
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

10.  Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation.

Authors:  N Kruse; B J Shen; S Arnold; H P Tony; T Müller; W Sebald
Journal:  EMBO J       Date:  1993-12-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.